The stock of Axsome Therapeutics, Inc. (NASDAQ:AXSM) reached all time low today, Feb, 9 and still has $2.35 target or 6.00% below today’s $2.50 share price. This indicates more downside for the $63.62 million company. This technical setup was reported by Barchart.com. If the $2.35 PT is reached, the company will be worth $3.82 million less. The stock decreased 1.96% or $0.05 during the last trading session, reaching $2.5. About 103,991 shares traded. Axsome Therapeutics, Inc. (NASDAQ:AXSM) has declined 59.08% since February 9, 2017 and is downtrending. It has underperformed by 75.78% the S&P500.
Among 3 analysts covering ePlus (NASDAQ:PLUS), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. ePlus had 14 analyst reports since August 7, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of PLUS in report on Friday, December 9 with “Hold” rating. The stock of ePlus inc. (NASDAQ:PLUS) earned “Buy” rating by Canaccord Genuity on Tuesday, January 5. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, November 5. Sidoti maintained the shares of PLUS in report on Thursday, May 26 with “Buy” rating. Zacks upgraded the stock to “Sell” rating in Friday, August 7 report. On Sunday, September 10 the stock rating was maintained by Stifel Nicolaus with “Hold”. Stifel Nicolaus downgraded the shares of PLUS in report on Friday, October 30 to “Hold” rating. As per Sunday, October 15, the company rating was maintained by Stifel Nicolaus. On Monday, October 12 the stock rating was downgraded by Sidoti to “Neutral”. The rating was downgraded by Sidoti on Friday, October 9 to “Neutral”. See ePlus inc. (NASDAQ:PLUS) latest ratings:
02/11/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $80.0 Maintain
15/10/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $75.0 Maintain
10/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $75.0 Maintain
Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, December 14 by Ladenburg Thalmann. The rating was initiated by Cantor Fitzgerald with “Buy” on Tuesday, December 15. Brean Capital initiated the stock with “Buy” rating in Monday, October 3 report.
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system disorders. The company has market cap of $63.62 million. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It currently has negative earnings. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain.
Since September 6, 2017, it had 0 buys, and 5 selling transactions for $2.29 million activity. 400 shares were sold by BOWEN BRUCE M, worth $33,028 on Wednesday, September 6. On Monday, October 2 MARRON MARK P sold $934,016 worth of ePlus inc. (NASDAQ:PLUS) or 10,000 shares. Another trade for 3,000 shares valued at $280,214 was made by Marion Elaine D on Monday, October 2.
The stock increased 5.02% or $3.5 during the last trading session, reaching $73.2. About 138,262 shares traded or 67.25% up from the average. ePlus inc. (NASDAQ:PLUS) has risen 75.66% since February 9, 2017 and is uptrending. It has outperformed by 58.96% the S&P500.
ePlus inc., an engineering-centric technology solutions provider, provides information technology services and products, flexible leasing and financing solutions, and enterprise supply management in the United States. The company has market cap of $1.04 billion. It operates through two divisions, Technology and Financing. It has a 18.12 P/E ratio. The Technology segment sells IT products, such as hardware, software, maintenance, software assurance, and services; and offers advanced professional and managed services, including data center infrastructure, networking, security, cloud, and collaboration, as well as ePlus managed, professional, security, staff augmentation, server and desktop support, and project management services.
Investors sentiment decreased to 1.48 in 2017 Q3. Its down 3.20, from 4.68 in 2017Q2. It worsened, as 17 investors sold ePlus inc. shares while 44 reduced holdings. 30 funds opened positions while 60 raised stakes. 12.25 million shares or 47.90% less from 23.51 million shares in 2017Q2 were reported. Pub Employees Retirement Sys Of Ohio invested in 20,954 shares or 0.01% of the stock. Tower Rech Limited Liability (Trc) invested 0.01% of its portfolio in ePlus inc. (NASDAQ:PLUS). 1.14 million are owned by Dimensional Fund L P. Ahl Partners Limited Liability Partnership, United Kingdom-based fund reported 2,531 shares. Thrivent For Lutherans reported 8,690 shares or 0% of all its holdings. Pinebridge Limited Partnership holds 0% of its portfolio in ePlus inc. (NASDAQ:PLUS) for 1,759 shares. Teachers Retirement System Of The State Of Kentucky holds 0.03% or 24,636 shares in its portfolio. Barclays Public Ltd Com holds 0% or 17,494 shares. Bridgeway Capital Management Incorporated reported 47,200 shares. California State Teachers Retirement Systems accumulated 0% or 21,032 shares. Amer Int Grp Inc invested 0% of its portfolio in ePlus inc. (NASDAQ:PLUS). United Svcs Automobile Association reported 8,760 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 570 shares in its portfolio. Prelude Capital Mgmt Ltd Liability Corp holds 700 shares. Moreover, Lsv Asset Management has 0% invested in ePlus inc. (NASDAQ:PLUS).